Compare Keysight Technologies Inc (KEYS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Keysight Technologies Inc trades at $352.53 (market cap $63.03B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Keysight Technologies Inc is far larger — about 12.9× Travere Therapeutics Inc. Common Stock's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KEYS | TVTX | |
|---|---|---|
Market Cap | $63.03B | $4.88B |
Volume | 1,168,526 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $387.90 | $67.52 |
52-Week Low | $162.19 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $63.17B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $357.59, down 5.32% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
The outlook remains positive with a consensus price target of $421.29, implying significant upside. Risks include elevated valuation multiples and supply constraints affecting near-term revenue conversion. Institutional sentiment is bullish, with 81% of analysts rating the stock a buy.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
